GLYAT suppresses liver cancer and clear cell renal cell carcinoma progression by downregulating ROCK1 expression.

ABSTRACT:

Background

The liver and kidney are important metabolic organs in the body and common sites of tumor occurrence. Glycine-N-acyltransferase (GLYAT) is primarily expressed in the liver and kidney and downregulated in several tumors. But its specific functions and molecular mechanisms in liver cancer and clear cell renal cell carcinoma (ccRCC) have not yet been fully elucidated. The aim of this study was to explore the role and clinical significance of GLYAT in liver cancer and ccRCC.

Methods

This study used proteomics technology to identify differentially expressed proteins in liver cancer. Western blot and immunohistochemistry (IHC) were used to analyze the protein expression pattern of GLYAT. assays were performed in liver cancer and ccRCC cells. Xenograft models in nude mic

SUBMITTER: Xia Y 

PROVIDER: S-EPMC11483444 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature